2026 has marked a significant turning point in biotech capital markets, not just a small comeback. Venture funding for biotech startups reached $9.1 billion in the first half of the year, the highest first-half total since 2022, while 13 biotech IPOs raised a combined $4.5 billion, with a median haul of nearly $302 million per offering, unusually high by recent standards, with the majority of this year’s debutants still trading above their offering price. Dealmaking has also maintained its pace, with 38 acquisitions closing in the same time period, placing the industry at its fastest M&A pace in at least seven years.
Underneath that broad comeback is a more unique validation story for RNA interference in particular. The market for RNAi treatments is expected to rise from $2.9 billion in 2025 to $3.6 billion in 2026. This growth comes after RNAi spent nearly two decades as a research curiosity before receiving its first licensed medicine in 2018. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has recently emerged as the clearest example of this transition, and the market’s reaction raises the question of whether the story has been properly priced.
The Quarter Itself
During Q1 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) exceeded $1 billion in quarterly product revenue for the first time in its history, with $1.036 billion in net product revenue, up 121% year-over-year and 4% sequentially over Q4 2025, on total revenue of $1.17 billion, up 96% year-over-year. AMVUTTRA alone delivered $890 million, bringing total TTR franchise revenue (AMVUTTRA plus ONPATTRO) to $910 million, up 153% from the previous year.
That growth completely flipped the company’s bottom line: GAAP net income was $206 million, compared to a $15.9 million loss in the same quarter the previous year, and GAAP income from operations came in at $268.6 million, up from a prior-year loss. A company that continued to burn cash a year ago is now solidly profitable on a GAAP basis.
The Growth Looks Durable, Not Front-loaded
The growth is also not driven by a single medicine, which is important for long-term viability. The rare disease franchise, GIVLAARI and OXLUMO, added $126 million, increasing 15% year-over-year, while AMVUTTRA’s worldwide rollout has reached seven markets, with payment negotiations still ongoing in the Spanish and French markets. This means that a significant portion of the revenue base is yet to be released.
Patient retention data confirms that the growth is sustained rather than sudden. Real-world adherence to vutrisiran has remained above 90% over the last two years, and the company has gained over 1,200 additional AMVUTTRA prescribers since its cardiomyopathy launch a year ago.
Is This Priced In? The Valuation Case Says Not Yet
Alnylam’s current forward P/E ratio of around 32.5x represents a sharp multiple compression relative to its early profitability phase, when nominal earnings skewed historical forward P/E ratios above 100x. This contraction reflects a fundamental biotech inflection instead of a typical GARP scenario: strong top-line growth and operating leverage are expanding net margins faster than equity re-ratings. Since forward earnings expectations have exceeded stock price appreciation, ALNY’s valuation has basically become de-risked as the company achieves steady-state earnings power.
Sentiment Check
Meanwhile, institutional stance shifted considerably during the first quarter. Insider Monkey’s Q1 2026 hedge fund database shows that 54 top funds maintained long holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at the end of the quarter, down from 67 in the previous quarter. Simultaneously, short interest represents 4.36% of the public float. While low in absolute terms, the short float compared to larger peers suggests that a portion of institutional traders is concerned about Alnylam’s ability to maintain its current growth rate through the second half of 2026.
Insider Monkey’s Bottom Line
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) represents a textbook asymmetric opportunity in which operational compounding and margin expansion have temporarily outperformed stock price appreciation. Rather than indicating waning enthusiasm, the company’s forward P/E ratio has been reduced to around 32.5x, suggesting the stock has undergone structural de-risking as nominal earnings give way to stable profitability. With quarterly product revenue surpassing $1 billion, two-year patient adherence above 90%, and major sell-side targets reaching $400, the underlying cash-flow trajectory remains solid. Investors should view the current valuation gap as a mispricing opportunity before institutional capital catches up with the company’s expanded net margins.
While we acknowledge the risk and potential of ALNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALNY and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center